Section Arrow
EDIT.NASDAQ
- Editas Medicine
Quotes are at least 15-min delayed:2026/01/09 07:37 EST
Pre Market
Last
 2.19
+0.05 (+2.34%)
Bid
2.16
Ask
2.2
High 2.19 
Low 2.19 
Volume 20 
Regular Hours (Closed)
Last
 2.14
-0.02 (-0.93%)
Day High 
2.15 
Prev. Close
2.16 
1-M High
2.7 
Volume 
1.23M 
Bid
2.16
Ask
2.2
Day Low
2.07 
Open
2.15 
1-M Low
1.95 
Market Cap 
210.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.11 
20-SMA 2.28 
50-SMA 2.48 
52-W High 4.5372 
52-W Low 0.9101 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.35/-1.32
Enterprise Value
231.24M
Balance Sheet
Book Value Per Share
0.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
32.31M
Operating Revenue Per Share
0.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1033-0.0223-17.75%-- 
Pre Market 0.1003 -0.003 -2.90%
ACRVAcrivon Therapeutics1.93-1.02-34.58%-- 
Pre Market 1.89 -0.04 -2.07%
VTYXVentyx Biosciences13.84+0.11+0.80%-- 
Pre Market 13.81 -0.03 -0.22%
MLTXMoonLake Immunotherapeutics14.34+3.05+27.02%-- 
Pre Market 15.11 +0.77 +5.37%
CRMDCorMedix7.51-3.66-32.77%5.05PE
Pre Market 7.55 +0.04 +0.53%
Industry overview quotes are at least 15 minutes delayed
Business Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.